FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978496616> ?p ?o ?g. }

• W1978496616 endingPage "966" @default.
• W1978496616 startingPage "961" @default.
• W1978496616 abstract "Clofarabine is a second generation nucleoside analogue with activity in adults with acute myeloid leukemia (AML). A phase I trial of clofarabine, idarubicin, and cytarabine (CIA) in relapsed and refractory AML had shown an overall response rate (ORR) of 48%. To explore this combination further, we conducted a phase II study of (CIA) in patients with newly diagnosed AML ≤60 years. Patients ≥18–60 years with AML and adequate organ function were enrolled. Induction therapy consisted of clofarabine (C) 20 mg m −2 IV daily (days 1–5), idarubicin (I) 10 mg m −2 IV daily (days 1–3), and cytarabine (A) 1 g m −2 IV daily (days 1–5). Patients in remission received up to six consolidation cycles (C 15 mg m −2 × 3, I 8 mg m −2 × 2, and A 0.75 g m −2 × 3). Fifty‐seven patients were evaluable. ORR was 79%. With a median follow up of 10.9 months, the median overall survival (OS) was not reached, the median event‐free survival (EFS) was 13.5 months. Most toxicities were ≤grade 2. Four week mortality was 2%. In subgroup analysis, patients ≤40 years had better OS ( P = 0.04) and EFS ( P = 0.04) compared to patients >40 years. Compared to historical patients treated with idarubicin and cyarabine (IA), the OS and EFS were significantly longer for CIA treated patients. In multivariate analysis, CIA retained its favorable impact on OS compared to IA. Thus, CIA is an effective and safe therapy for patients ≤60 years with newly diagnosed AML. Am. J. Heamtol. 88:961–966, 2013. © 2013 Wiley Periodicals, Inc." @default.
• W1978496616 created "2016-06-24" @default.
• W1978496616 creator A5000750846 @default.
• W1978496616 creator A5015140142 @default.
• W1978496616 creator A5020340537 @default.
• W1978496616 creator A5022647201 @default.
• W1978496616 creator A5028845635 @default.
• W1978496616 creator A5040869301 @default.
• W1978496616 creator A5046097970 @default.
• W1978496616 creator A5049385583 @default.
• W1978496616 creator A5055045706 @default.
• W1978496616 creator A5057822243 @default.
• W1978496616 creator A5061026876 @default.
• W1978496616 creator A5074389270 @default.
• W1978496616 creator A5079262854 @default.
• W1978496616 creator A5082102743 @default.
• W1978496616 creator A5083096702 @default.
• W1978496616 creator A5084290698 @default.
• W1978496616 creator A5086233229 @default.
• W1978496616 creator A5088307376 @default.
• W1978496616 creator A5090435894 @default.
• W1978496616 date "2013-09-09" @default.
• W1978496616 modified "2023-10-15" @default.
• W1978496616 title "Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia" @default.
• W1978496616 cites W101202223 @default.
• W1978496616 cites W1492445977 @default.
• W1978496616 cites W1976904568 @default.
• W1978496616 cites W1982766090 @default.
• W1978496616 cites W1996815004 @default.
• W1978496616 cites W1999071024 @default.
• W1978496616 cites W2007386979 @default.
• W1978496616 cites W2024950851 @default.
• W1978496616 cites W2034506866 @default.
• W1978496616 cites W2040489908 @default.
• W1978496616 cites W2069448515 @default.
• W1978496616 cites W2109065151 @default.
• W1978496616 cites W2116171965 @default.
• W1978496616 cites W2117844516 @default.
• W1978496616 cites W2119626196 @default.
• W1978496616 cites W2125695832 @default.
• W1978496616 cites W2139717439 @default.
• W1978496616 cites W2143342566 @default.
• W1978496616 cites W2144395887 @default.
• W1978496616 cites W2158022600 @default.
• W1978496616 cites W2167036588 @default.
• W1978496616 cites W2318674152 @default.
• W1978496616 cites W4237543851 @default.
• W1978496616 cites W49953563 @default.
• W1978496616 doi "https://doi.org/10.1002/ajh.23544" @default.
• W1978496616 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4110914" @default.
• W1978496616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23877926" @default.
• W1978496616 hasPublicationYear "2013" @default.
• W1978496616 type Work @default.
• W1978496616 sameAs 1978496616 @default.
• W1978496616 citedByCount "43" @default.
• W1978496616 countsByYear W19784966162013 @default.
• W1978496616 countsByYear W19784966162014 @default.
• W1978496616 countsByYear W19784966162015 @default.
• W1978496616 countsByYear W19784966162016 @default.
• W1978496616 countsByYear W19784966162017 @default.
• W1978496616 countsByYear W19784966162018 @default.
• W1978496616 countsByYear W19784966162019 @default.
• W1978496616 countsByYear W19784966162020 @default.
• W1978496616 countsByYear W19784966162021 @default.
• W1978496616 countsByYear W19784966162023 @default.
• W1978496616 crossrefType "journal-article" @default.
• W1978496616 hasAuthorship W1978496616A5000750846 @default.
• W1978496616 hasAuthorship W1978496616A5015140142 @default.
• W1978496616 hasAuthorship W1978496616A5020340537 @default.
• W1978496616 hasAuthorship W1978496616A5022647201 @default.
• W1978496616 hasAuthorship W1978496616A5028845635 @default.
• W1978496616 hasAuthorship W1978496616A5040869301 @default.
• W1978496616 hasAuthorship W1978496616A5046097970 @default.
• W1978496616 hasAuthorship W1978496616A5049385583 @default.
• W1978496616 hasAuthorship W1978496616A5055045706 @default.
• W1978496616 hasAuthorship W1978496616A5057822243 @default.
• W1978496616 hasAuthorship W1978496616A5061026876 @default.
• W1978496616 hasAuthorship W1978496616A5074389270 @default.
• W1978496616 hasAuthorship W1978496616A5079262854 @default.
• W1978496616 hasAuthorship W1978496616A5082102743 @default.
• W1978496616 hasAuthorship W1978496616A5083096702 @default.
• W1978496616 hasAuthorship W1978496616A5084290698 @default.
• W1978496616 hasAuthorship W1978496616A5086233229 @default.
• W1978496616 hasAuthorship W1978496616A5088307376 @default.
• W1978496616 hasAuthorship W1978496616A5090435894 @default.
• W1978496616 hasBestOaLocation W19784966162 @default.
• W1978496616 hasConcept C126322002 @default.
• W1978496616 hasConcept C141071460 @default.
• W1978496616 hasConcept C2777198975 @default.
• W1978496616 hasConcept C2778041864 @default.
• W1978496616 hasConcept C2778729363 @default.
• W1978496616 hasConcept C2779117419 @default.
• W1978496616 hasConcept C71924100 @default.
• W1978496616 hasConcept C90924648 @default.
• W1978496616 hasConceptScore W1978496616C126322002 @default.
• W1978496616 hasConceptScore W1978496616C141071460 @default.
• W1978496616 hasConceptScore W1978496616C2777198975 @default.
• W1978496616 hasConceptScore W1978496616C2778041864 @default.

• next